Abstract
This study uses data from the National Cancer Database to examine the population-level efficacy of novel therapies for advanced-stage melanoma.
MeSH terms
-
Aged
-
Antibodies, Monoclonal* / classification
-
Antibodies, Monoclonal* / therapeutic use
-
Cell Cycle Checkpoints* / drug effects
-
Cell Cycle Checkpoints* / immunology
-
Female
-
Humans
-
Immunotherapy / methods*
-
Ipilimumab / therapeutic use
-
Male
-
Melanoma / drug therapy*
-
Melanoma / mortality
-
Melanoma / pathology
-
Middle Aged
-
Molecular Targeted Therapy / methods*
-
Neoplasm Staging
-
Protein Kinase Inhibitors* / classification
-
Protein Kinase Inhibitors* / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / mortality
-
Skin Neoplasms / pathology
-
Survival Analysis
-
Treatment Outcome
-
United States / epidemiology
-
Vemurafenib / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Ipilimumab
-
Protein Kinase Inhibitors
-
Vemurafenib